Other News To Note
Friday, July 15, 2011
Impax Pharmaceuticals, of Hayward, Calif., received an award of up to $400,000 from The Michael J. Fox Foundation for development of its Parkinson's candidate, IPX066, an extended-release carbidopa-levodopa product. The funding will support a study of dosing conversion from CD-LD to IPX066 and an open-label extension safety study.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.